A Phase II, Multicenter, Single-Arm, Open-Label Study of Parsaclisib, a PI3Kd Inhibitor, in Relapsed or Refractory Follicular Lymphoma in China

被引：0

作者：

Zheng, Zhong ^{[1
]}

Zhang, Huilai ^{[2
]}

Wang, Jingwen ^{[3
]}

Zhou, Keshu ^{[4
]}

Zhang, Li ^{[5
]}

Zhou, Hui ^{[6
]}

Zhang, Qingyuan ^{[7
]}

Zhao, Weili ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Natl Res Ctr Translat Med Shanghai,Sch Med, State Key Lab Med Genom,Shanghai Inst Hematol, Shanghai, Peoples R China

[2] Tianjin Med Univ Canc Inst Hosp, Dept Lymphoma, Tianjin, Peoples R China

[3] Beijing Tongren Hosp, Beijing, Peoples R China

[4] Zhengzhou Univ, Henan Canc Hosp, Dept Hematol, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[5] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Sichuan, Peoples R China

[6] Hunan Canc Hosp, Dept Lymphoma & Hematol, Changsha, Peoples R China

[7] Harbin Med Univ Canc Hosp, Harbin, Peoples R China

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-150002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3536

引用

页数：4